Choosing the Right Treatment Option for the Right R/M HNSCC Patient: Should We Adhere to PFE for First-Line Therapy?

BACKGROUND: The landmark EXTREME trial established cisplatin, 5-fluorouracil and cetuximab (PFE) as first-line chemotherapy (1L-ChT) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). We were interested in outcome differences of R/M HNSCC in 1L-ChT and factors influencing ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Lübbers, Katharina, Pavlychenko, Mykola, Wald, Theresa, Wiegand, Susanne, Dietz, Andreas, Zebralla, Veit, Wichmann, Gunnar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329655/
https://www.ncbi.nlm.nih.gov/pubmed/34354955
http://dx.doi.org/10.3389/fonc.2021.715297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329655/
https://www.ncbi.nlm.nih.gov/pubmed/34354955
http://dx.doi.org/10.3389/fonc.2021.715297

Ejemplares similares